Alert: FTC Challenges 'No-AG' Agreement as Illegal Reverse Payment

Alert: FTC Challenges 'No-AG' Agreement as Illegal Reverse Payment


On March 30 the US Federal Trade Commission filed suit in federal court alleging that settlements of patent litigation in the pharmaceutical industry in which a pioneer firm agrees not to market an "authorized generic" violate antitrust law. The FTC is seeking disgorgement of what it alleges are "ill-gotten gains" from Endo Pharmaceuticals, Inc. and a number of generic firms in the agency's second suit challenging patent litigation settlements since the Supreme Court's decision in FTC v.



from Biotech News